Skip to main content
Caplight Logo









Narval

Narval

Private
ZapopanHealthcare & Life Scienceshttps://narvalbio.com/

Last Round

Accelerator

May 29, 2024

Total Funding Raised

$4.02M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Narval is a biotechnology company that develops synthetic Antibody Mimetic Proteins™ designed to replace conventional monoclonal antibodies in therapeutic applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Defense Tech

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

synthetic antibody mimetic proteinsAMPsdrug discoveryAI drug discoveryin-silico drug designtherapeutic proteinslocalized drug deliverybiotechnologymarine biotechnologybiodefenseanimal healthgenerative AIprotein engineeringbiotech startupantibody alternatives

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Narval Comparables

Compare Narval with similar companies based on industry and business-model similarity.

Narval comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Elasmogen
85%
Nabla Bio
70%
AbCellera Biologics Inc.
65%

Narval Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorMay 29, 2024
AcceleratorMar 11, 2024

Key People

Founding team and executive leadership

Alejandro Nuño Ayala

Founder Chief Scientific Officer

Founding Team

Jose Luis Nuno

Founder And CEO

Founding Team

Narval Investors

Notable investors and investment history

Narval investors
InvestorRounds
MedTech InnovatorAccelerator
TechstarsAccelerator
BioTools InnovatorAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors increased 35% MoM, reaching 3.8K.

  • Mar 11, 2024

    $20K round led by Techstars

Narval Filings

Explore SEC and related filing metadata, where available.

Narval filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Narval's valuation, stock price, and market status.

Is Narval a public or private company?

Narval is a private company.

What is the current stock price of Narval?

Narval is a private company with no public stock price. No recent secondary market data is available.

How much is Narval worth (valuation)?

Valuation information for Narval is not publicly available.

Can I buy Narval stock?

Narval shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Narval's last funding round?

Narval's most recent funding round was Accelerator on March 11, 2024.

Who are the main investors in Narval?

Key investors in Narval include Techstars, Strobe Ventures.

Will Narval IPO soon?

No public IPO plans have been announced for Narval.

How can I track Narval secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Narval's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersZapopan
Employee Range2
Year Founded2023
Last FundingMay 29, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?